Compare DFDV & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DFDV | ALDX |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | 16 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.4M | 103.1M |
| IPO Year | N/A | 2014 |
| Metric | DFDV | ALDX |
|---|---|---|
| Price | $2.93 | $2.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $45.00 | $5.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 05-13-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.58 | N/A |
| Revenue Next Year | $23.65 | N/A |
| P/E Ratio | $0.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $1.07 |
| 52 Week High | $32.00 | $6.18 |
| Indicator | DFDV | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 64.83 |
| Support Level | $2.61 | $1.49 |
| Resistance Level | $5.22 | $2.27 |
| Average True Range (ATR) | 0.29 | 0.15 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 35.97 | 88.39 |
DeFi Development Corp is a U.S. company committed to building its treasury around Solana (SOL), a fast-growing blockchain infrastructure platform. This equity delivers shareholders tangible exposure to SOL price movement and staking rewards, making the firm a proxy for the Solana ecosystem. The treasury extends to running its own validator infrastructure, allowing DFDV to actively participate in and benefit from the Solana network expansion. The firm has two segments: Digital Asset Treasury ("Treasury") and Real Estate Platform ("Real Estate"). The company generates the majority of its revenue from the Treasury segment.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.